Julien Mazieres , R. Veillon , A. Cortot , R. Ferrara , E. Felip , M. Garassino , X. Le , M. Thomas , H. Sakai , E. Smit , J. Raskin , S. Viteri , J.C-H. Yang , M-J. Ahn , Y-L. Wu , J. Zhao , V. Ghori , R. Bruns , A. Johne , P. Paik
{"title":"81P:替波替尼治疗METexon 14 (METex14)跳过非小细胞肺癌(NSCLC)的患者:≥3年的随访结果","authors":"Julien Mazieres , R. Veillon , A. Cortot , R. Ferrara , E. Felip , M. Garassino , X. Le , M. Thomas , H. Sakai , E. Smit , J. Raskin , S. Viteri , J.C-H. Yang , M-J. Ahn , Y-L. Wu , J. Zhao , V. Ghori , R. Bruns , A. Johne , P. Paik","doi":"10.1016/S1556-0864(25)00276-X","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S59-S60"},"PeriodicalIF":21.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"81P: Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes\",\"authors\":\"Julien Mazieres , R. Veillon , A. Cortot , R. Ferrara , E. Felip , M. Garassino , X. Le , M. Thomas , H. Sakai , E. Smit , J. Raskin , S. Viteri , J.C-H. Yang , M-J. Ahn , Y-L. Wu , J. Zhao , V. Ghori , R. Bruns , A. Johne , P. Paik\",\"doi\":\"10.1016/S1556-0864(25)00276-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"20 3\",\"pages\":\"Pages S59-S60\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S155608642500276X\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S155608642500276X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
81P: Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.